Von Willebrand Disease
Von Willebrand Disease Market

Von Willebrand Disease 


Von Willebrand Disease (VWD) is a lifelong bleeding disorder in which your blood doesn't clot properly. People with the disease have low levels of von Willebrand factor, a protein that helps blood clot, or the protein doesn't perform as it should.


Most people with the disease are born with it, having inherited it from one or both parents. Von Willebrand’s disease can't be cured. But with treatment and self-care, most people with this disease can lead active lives.


Von Willebrand Disease Epidemiology Segmentation in the United States 


  • Total Von Willebrand Disease diagnosed prevalent population
  • Gender-specific Von Willebrand Disease diagnosed prevalent population
  • Type-specific Von Willebrand Disease diagnosed prevalent population
  • Age-specific Von Willebrand Disease diagnosed as prevalent population 


Von Willebrand Disease Epidemiological Insights Observed in the United States (2020)


  • The total diagnosed prevalent cases of Von Willebrand Disease was 12,505.
  • Females account for 55.50% of diagnosed prevalent cases of Von Willebrand Disease.
  • Gender-specific diagnosed prevalent populations of Von Willebrand Disease in males were observed to be 5,565 whereas in females it was found to be 6,941.


Von Willebrand Disease Market Insight


The market size of Von Willebrand Disease in the United States was found to be USD 309 million in 2020.  


Von Willebrand Disease Market Drivers


  • Raising awareness
  • Regulatory approvals
  • Pediatric population


Von Willebrand Disease Market Barriers


  • Lack of robust pipeline
  • Diagnostic dilemma
  • Lack of assay for anti-VWF alloantibody 


Von Willebrand Disease Marketed Therapies


The marketed drugs  in the Von Willebrand Disease market are


  • Vonvendi
  • Humate-P/Haemate P
  • Wilate
  • Desmopressin
  • Alphanate, and several others


Von Willebrand Disease Key Players 


The key players working in the Von Willebrand Disease market are


  • Shire
  • CSL Behring
  • Octapharma
  • Ferring Pharmaceuticals
  • Grifols Biological Inc., and several others